Advertisement
Canada markets closed
  • S&P/TSX

    22,308.93
    +361.53 (+1.65%)
     
  • S&P 500

    5,222.68
    +94.89 (+1.85%)
     
  • DOW

    39,512.84
    +837.14 (+2.16%)
     
  • CAD/USD

    0.7316
    +0.0007 (+0.10%)
     
  • CRUDE OIL

    78.20
    -0.06 (-0.08%)
     
  • Bitcoin CAD

    83,715.29
    +382.54 (+0.46%)
     
  • CMC Crypto 200

    1,260.20
    -52.43 (-3.99%)
     
  • GOLD FUTURES

    2,366.90
    -8.10 (-0.34%)
     
  • RUSSELL 2000

    2,059.78
    +24.06 (+1.18%)
     
  • 10-Yr Bond

    4.5040
    +0.0040 (+0.09%)
     
  • NASDAQ

    16,340.87
    +184.57 (+1.14%)
     
  • VOLATILITY

    12.55
    -0.94 (-6.97%)
     
  • FTSE

    8,433.76
    +261.61 (+3.20%)
     
  • NIKKEI 225

    38,229.11
    -44.99 (-0.12%)
     
  • CAD/EUR

    0.6790
    +0.0003 (+0.04%)
     

Valeant shares jump after a short-seller's new report offers no 'kill shot'

The company logo of Valeant Pharmaceuticals International Inc is seen at its headquarters in Laval, Quebec May 19, 2015.   REUTERS/Christinne Muschi
The company logo of Valeant Pharmaceuticals International Inc is seen at its headquarters in Laval, Quebec May 19, 2015. REUTERS/Christinne Muschi

(Thomson Reuters)
Company logo of Valeant Pharmaceuticals International Inc is seen at its headquarters in Laval

Shares of Valeant rose on Monday after a short-seller's updated report offered no bombshell allegations against the Canadian pharmaceutical company.

"For those of you expecting a 'kill shot', you can stop reading here," a new report from Citron Research, the California-based short selling firm led by Andrew Left, said.

"While Citron has been at the nexus of information on this story, we will not be releasing new allegations against Valeant in this piece, as we believe that it is not our responsibility to be the judge, jury, and executioner of the company’s deeds. Yes, we have reviewed numerous data points strongly suggesting that Valeant’s operation is far 'dirtier' than just Philidor, we are passing all new information on to the mainstream media investigative reports, whose legal teams are far deeper than those at Citron."

ADVERTISEMENT

Valeant's share price was last up $7.23, or 7.7%, at $101 per share.

On Friday at 11:45 a.m. ET, while hedge fund manager Bill Ackman was hosting a four-hour conference call defending his position in Valeant, Citron tweeted that it's updated report would have more dirt.

"$VRX has a better chance of going to 0 than $HLF ever will," Citron tweeted, adding that the story was "dirtier than anyone has reported!!"

That isn't the case anymore. Citron Research said that it's work on Valeant is done. Citron also said that it thinks the company's stock price will trade at much lower levels than the current price.

Shares of Valeant have cratered more than 40% since Citron published its report nearly two weeks ago suggesting Valeant may be operating as an Enron-like fraud.

Valeant has denied Citron's allegations. The company has also had its outside counsel meet with SEC to request that they investigate Citron.

Here's a chart of today's price movement:

Valeant
Valeant

(Google Finance)

And here's a chart since the Citron report came out on Oct. 21:

Valeant
Valeant

(Google Finance)

NOW WATCH: JAMES ALTUCHER: 'Warren Buffett is a f-----g liar'



More From Business Insider